Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol

M. Soehle1*, M. Kuech1, M. Grube1, S. Wirz1,2, S. Kreuer3, A. Hoeft1, J. Bruhn1,4 and R. K. Ellerkmann1

1 Department of Anaesthesiology and Intensive Care Medicine, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany
2 Department of Anaesthesiology and Intensive Care Medicine, CURA Hospital, Bad Honnef, Germany
3 Department of Anaesthesiology and Intensive Care Medicine, University of Saarland, Homburg, Saar, Germany
4 Department of Anaesthesia, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

* Corresponding author. E-mail: martin.soehle@ukb.uni-bonn.de

Both volatile and i.v. anaesthetics induce characteristic electroencephalographic (EEG) changes, which are used to assess the depth of anaesthesia. Different parameters have been evaluated to quantify this effect,1 for example, spectral edge and median EEG frequency, state and response entropy, and indices such as the bispectral index (BIS), the Narcotrend index, and the patient state index (PSI). These indices which quantify anaesthetic depth using the same range from 100 (awake state) to 0 (deep anaesthesia), however, are based on different algorithms.1

The PSI monitor records four EEG channels and calculates the PSI based on the quantitative EEG analysis of the power within the \(\alpha\), \(\beta\), \(\delta\), and \(\theta\)-frequency bands, and also the temporal and spatial gradients occurring among these frequency bands when changing anaesthetic depth.2

The BIS monitor analyses the EEG frequencies too; however, it considers not only the power but the phase information as well, which are derived from fast Fourier transformation. A process called bispectral analysis investigates the phase coupling between different EEG frequencies and contributes to both the BIS and the naming of the monitor itself.3

Previously, we analysed the performance of the PSI and BIS monitors to predict the depth of sevoflurane anaesthesia...
and obtained comparable results. Only slight differences between the monitors were noticed: whereas the BIS reacted faster to changes in sevoflurane concentrations, the PSI made a better use of the index range. In addition to these previous results obtained by using a volatile anaesthetic, we performed a study applying an i.v. drug: the aim of the current study was to analyse the pharmacodynamic effects of propofol on PSI and BIS and to compare the performance of both monitors to predict the depth of propofol anaesthesia.

Methods

After approval of the University of Bonn Ethics Committee (reference number 203/03) and written informed consent, we evaluated 17 patients undergoing otorhinolaryngologic surgery. Age was restricted to 18–65 yr, and ASA physical status to I or II. Pregnancy and any disease or (current) treatment affecting the central nervous system were exclusion criteria.

Patients were instructed to fast for 6 h and received midazolam 7.5 mg p.o. 45 min before induction of anaesthesia. Standard anaesthetic monitoring was applied upon arrival in the induction room, and mean arterial pressure (MAP) was measured non-invasively at intervals of 2.5 min. The forehead skin was cleaned with 70% isopropanol to improve skin conductance, and both EEG electrodes (Physiometrix PArray2 Sensor®, BIS XP-Sensor®) were applied subsequently according to the manufacturer’s instructions. The Hospira (formerly Physiometrix) PSA 4000 monitor® (Hospira Inc., Lake Forest, IL, USA) and the Aspect A-2000 BIS monitor® (version XP, Aspect Medical Systems, Newton, MA, USA) were used to record the EEG simultaneously and continuously.

A 14 G venous catheter was inserted into a large forearm vein and lactated Ringer’s solution was infused at a constant rate of 500 ml h⁻¹. Anaesthesia was induced solely by a continuous propofol 2% infusion at a rate of 2000 mg h⁻¹. The propofol infusion was stopped (Fig. 1) as soon as substantial burst suppression occurred (burst suppression rate >60% according to the BIS monitor) or arterial hypotension occurred (MAP < 60 mm Hg). After discontinuation of the propofol application, depth of anaesthesia diminished slowly. When the BIS recovered to values >60, the propofol infusion was started again (Fig. 1) at an identical rate of 2000 mg h⁻¹ until a burst suppression rate >60% or an MAP < 60 mm Hg was reached. Thereafter, propofol infusion was discontinued and started again as mentioned above to perform further cycles of increasing and decreasing propofol plasma concentration. After a maximum of three cycles—or sooner if necessary due to the OR management requirements—EEG measurements were stopped and patients received opioids and neuromuscular blocking agents for subsequent intubation and surgery. Until that time, patients breathed spontaneously during the entire study period. Fraction of inspired oxygen was reduced from 1.0 at preoxygenation to 0.5 during the study.

PSI (release 3.00.09, averaging time 25 s, PSI value updated every 1.25 s), BIS (version 4.0, smoothing time 15 s, BIS value updated every second), and haemodynamic data (S/5 monitor®, GE Healthcare, Helsinki, Finland) were stored simultaneously every 5 s using software supplied by the manufacturer (Aspect: Winlog software; Datex Ohmeda: S/5 Collect software V 4.0).

Arterial propofol plasma concentrations were calculated using an Excel spreadsheet described by Bruhn and Bouillon based on the pharmacokinetic data set published by Schnider and colleagues. The propofol effect-site concentration (Cₑ) was obtained by simultaneous pharmacokinetic–pharmacodynamic (pk/pd) modelling. First, Cₑ was estimated using the differential equation:

\[
\frac{dC_e}{dt} = (C_{pl} - C_e) \times k_{e0}
\]

where \(C_{pl}\) is the plasma concentration of propofol, and \(k_{e0}\) denotes the first-order rate constant determining the efflux from the effect site. In practice, \(k_{e0}\) is approximated until the hysteresis loop between \(C_e\) and the EEG variable (BIS, PSI) has been collapsed. Secondly, a classic fractional sigmoid relation between \(C_e\) and the EEG effect \(E\) (BIS, PSI) was assumed:

\[
E = E_0 + \left( E_{max} - E_0 \right) \left( \frac{C_e}{C_{e50} + C_e^\gamma} \right)
\]

where \(E_0\) denotes the EEG effect in the absence of propofol (=baseline or awake state), and \(E_{max}\) is the EEG value corresponding to the maximum propofol effect. \(C_{e50}\) describes the propofol effect-site concentration that causes 50% of the maximum EEG effect, and \(\gamma\) quantifies the slope of the sigmoid relationship between \(C_e\) and \(E\).

Pkd parameters were determined offline using two different approaches: in a Fisherian statistics approach (also...
known as classic two-stage approach), pk/pd parameters were first obtained for each individual patient (individual fit) applying the solver tool of the Excel 2000 software (Microsoft, Redmond, WA, USA): this tool was used to perform a sigmoid regression of the EEG effect based on \( C_e \). To quantify the goodness of the sigmoid fit, the coefficient of determination \( \rho^2 \) was calculated as

\[
\rho^2 = 1 - \frac{\sum (E_{\text{measured}} - E_{\text{calculated}})^2}{\sum (E_{\text{measured}} - E_{\text{measured}})^2}
\]

where \( E_{\text{measured}} \) is the averaged measured EEG effect. \( k_{e0} \) and the pd parameters \( E_0, E_{\text{max}}, C_{50}, \) and \( \gamma \) were simultaneously optimized by minimizing the ordinary least squares, which resulted from the difference between observed and estimated EEG effect. This yielded a collapse of the above-mentioned hysteresis loop. Subsequently, pk/pd parameters were averaged among all 17 patients.

In a second Bayesian statistics approach, it was assumed that a 'typical value' for the pk/pd parameters exist within a given patient population (population fit). Furthermore, it was hypothesized that additional random effects affect those pk/pd parameters, which are inter- and intra-individual variabilities. Whereas inter-individual variability reflects true biologic variability, intra-individual variability can be regarded as measurement noise or residual error. The NONMEM (NONlinear Mixed Effects Modelling) software (version V, GloboMax, Hanover, MD, USA) was used to perform this approach. \( k_{e0} \) and the pharmacodynamic parameters were estimated directly (in contrast to the above-mentioned two-stage approach) without fitting the pharcomkinetic model itself. To do so, the so-called first-order conditional estimation method was applied. Inter-individual variability was calculated for \( C_{50} \) and \( k_{e0} \), and the intra-individual variability \( \sigma \) (residual error) of the EEG effect (BIS, PSI) was estimated using an additive error model:

\[
E_{\text{observed}} = E_{\text{expected}} + \varepsilon
\]

where \( E_{\text{observed}} \) and \( E_{\text{expected}} \) refer to the observed and predicted EEG effects, respectively, and \( \varepsilon \) is a normally distributed random variable with mean zero and variance \( \sigma^2 \). The software optimized the pk/pd parameters to obtain a close agreement between observed and estimated EEG effect: in statistical terms, NONMEM maximizes the likelihood that the observed EEG effect would have been observed based on the propofol \( C_{\text{pl}} \) data if the pk/pd parameters were chosen and the intra- and inter-individual variabilities were estimated as suggested by NONMEM assuming a certain (here: sigmoid) EEG effect model.

For measurement and comparison of the performance of anaesthetic depth monitors, the prediction probability \( P_k \) by which the EEG variable (BIS, PSI) correctly predicted the propofol effect-site concentration was calculated according to Smith and colleagues applying his Excel software program PKMACRO. \( P_k \) itself is a non-parametric measure ranging between 0 and 1. An anaesthetic depth monitor that always predicts depth of anaesthesia correctly will obtain a \( P_k \) value of 1, whereas a monitor that performs no better than by (50:50) chance will be characterized by a \( P_k \) value of 0.5. Since propofol concentration increases as BIS and PSI decrease, the actual \( P_k \) value we measure is \( 1 - P_k \). Finally, Pearson’s product-moment correlation coefficient \( \rho \) and its square \( \rho^2 \) (coefficient of determination) were calculated to provide information on the goodness of the linear fit between PSI and BIS.

**Statistical analysis**

The study was designed to detect a change in the mean \( P_k \) value of 0.075, that is, 75% of the expected standard deviation (so) of the \( P_k \) value of 0.1 (as derived from our previous study). At a desired power of 0.8 and an \( \alpha \) of 0.05, 17 patients are required to do so, plus one additional patient to correct for a possible drop-out.

Statistical analysis was performed using the SigmaStat software (Jandel Scientific, Erkrath, Germany) applying Student’s t-test for paired samples in the case of normal distributed data. Otherwise, the Wilcoxon signed-rank test was performed. To comply with multiple comparisons, Bonferroni’s correction was applied and statistical significance was assumed at \( P<0.01 \) accordingly. Data are presented as mean (so) for the Fisherian and as typical value for the Bayesian approach.

**Results**

The 17 patients (seven women and 10 men) were 36 (12) yr old (mean (so)), had a body weight of 74 (17) kg, a height of 172 (11) cm, and a BMI of 25.0 (4.4) kg m\(^{-2}\).

PSI and BIS data from all 17 patients were available for final data analysis: one-and-a-half cycles of in- and decreasing propofol concentrations were analysed in one patient, two cycles in nine patients, and three cycles in seven patients. The endpoint of a burst suppression ratio of 60% was reached in all patients except for one, in which the propofol infusion was stopped at a burst suppression rate of 36% since the endpoint of an MAP < 60 mm Hg was attained.

**Individual pk/pd fitting**

The pk/pd parameters obtained in the individual patients are shown in Table 1. \( E_{\text{max}} \) was significantly lower (\( P=0.007 \), Wilcoxon signed-rank test) for PSI [0.3 (1.1)] when compared with BIS [5.3 (6.7)], and \( \gamma \) was significantly higher (\( P<0.01 \), paired t-test) for PSI [2.18 (0.57)] as for BIS [1.75 (0.41)]. In addition, a significantly smaller \( k_{e0} \) (\( P=0.005 \), paired t-test) was observed using the PSI monitor [\( k_{e0}=0.088 \) (0.29)] when compared with the BIS monitor [\( k_{e0}=0.104 \) (0.24)]. A close sigmoid relationship between \( C_e \) and PSI [\( r^2=0.91 \) (0.05)] or BIS [\( r^2=0.92 \) (0.03)] was obtained in individual patients, and the prediction probability of PSI [\( P_k=0.87 \) (0.05)] and BIS [\( P_k=0.86 \) (0.05)] to predict the propofol effect-site concentration did not differ statistically from each other (\( P=0.74 \), paired t-test).
The sigmoid relationship between the propofol effect-site concentration and the PSI and BIS as obtained by population-based fitting is shown in Figures 2 and 3, respectively. An intra-individual variability (residual error) of $s = 7.7$ and 6.4 was obtained for PSI and BIS, respectively (Table 1). The typical value of $E_{\text{max}}$ was smaller for PSI (1.9) as for BIS (8.6), whereas the other pk/pd parameters were comparable between the monitors. The recommended intraoperative range for PSI (50–25) and BIS (60–40) corresponded to propofol effect-site concentrations of 1.2–2.6 and 1.4–2.7 $\mu$g ml$^{-1}$, respectively (Fig. 4).

**Table 1** Pharmacokinetic and -dynamic parameters in comparison between PSI and BIS. Parameters were obtained by individual and population-based fitting. A sigmoid relationship between propofol effect-site concentration and EEG effect (BIS and PSI) was assumed. Data are expressed as mean (SD) for the individual fits and as typical value (so) for the population fit. *P<0.01 vs BIS. PSI, patient state index; BIS, bispectral index; $E_0$, EEG effect without anaesthesia; $E_{\text{max}}$, EEG effect corresponding to maximum drug effect; $C_{50}$, propofol effect-site concentration that caused 50% of the maximum EEG effect; $\gamma$, slope of the sigmoid relationship; $k_e$, effect-site efflux constant; $\rho^2$, coefficient of determination; $P_K$, prediction probability by which the EEG variable (BIS, PSI) correctly predicted the propofol effect-site concentration; $\sigma$, intra-individual EEG variability (=residual error)

<table>
<thead>
<tr>
<th>Fit</th>
<th>PSI</th>
<th>BIS</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Individual</td>
<td>Population</td>
<td>Individual</td>
<td>Population</td>
</tr>
<tr>
<td>$E_0$</td>
<td>86.9 (12.3)</td>
<td>89.3</td>
<td>92.0 (7.0)</td>
<td>92.3</td>
</tr>
<tr>
<td>$E_{\text{max}}$</td>
<td>0.3 (1.1)</td>
<td>1.9</td>
<td>5.3 (6.7)*</td>
<td>8.6</td>
</tr>
<tr>
<td>$C_{50}$ (µg ml$^{-1}$)</td>
<td>1.87 (0.78)</td>
<td>1.38 (0.86)</td>
<td>1.94 (0.52)</td>
<td>1.92 (0.82)</td>
</tr>
<tr>
<td>$\gamma$</td>
<td>2.18 (0.57)</td>
<td>1.60</td>
<td>1.75 (0.41)*</td>
<td>1.48</td>
</tr>
<tr>
<td>$k_e$ (min$^{-1}$)</td>
<td>0.088 (0.029)</td>
<td>0.103 (0.210)</td>
<td>0.104 (0.024)*</td>
<td>0.131 (0.206)</td>
</tr>
<tr>
<td>$\rho^2$</td>
<td>0.913 (0.054)</td>
<td>0.922 (0.033)</td>
<td>0.863 (0.051)</td>
<td></td>
</tr>
<tr>
<td>$P_K$</td>
<td>0.867 (0.053)</td>
<td>7.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\sigma$</td>
<td></td>
<td>6.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig 2 The relationship between the propofol effect-site concentration and PSI is shown for the ‘typical patient’ as obtained by population fit using NONMEM. The residual data of the individual patients are marked by blue circles.

Fig 3 The response of the BIS to changes in the propofol effect-site concentration is displayed for the ‘typical patient’ as revealed by population fit using the NONMEM software. The blue triangles indicate the residual data of the individual patients.

Fig 4 For the recommended ranges (shown as bars on the left and right ordinate) of the PSI (25–50) and the BIS (40–60), the corresponding propofol effect-site concentration site ranges (displayed as bars on the abscissa) are shown. The relation is based on the pharmacodynamic effect of propofol on BIS (blue line) and PSI (dotted green line) for the ‘typical patient’ as revealed by NONMEM.

### Population-based pk/pd fitting

The sigmoid relationship between the propofol effect-site concentration and the PSI and BIS as obtained by population-based fitting is shown in Figures 2 and 3, respectively. An intra-individual variability (residual error) of $\sigma=7.7$ and 6.4 was obtained for PSI and BIS, respectively (Table 1). The typical value of $E_{\text{max}}$ was smaller for PSI (1.9) as for BIS (8.6), whereas the other pk/pd parameters were comparable between the monitors. The recommended intraoperative range for PSI (50–25) and BIS (60–40) corresponded to propofol effect-site concentrations of 1.2–2.6 and 1.4–2.7 $\mu$g ml$^{-1}$, respectively (Fig. 4).
Correlation between BIS and PSI

A close and significant correlation between BIS and PSI was found ($r^2=0.866, P<0.001$). For PSI values between 25 and 50—the recommended range for general anaesthesia—44% of corresponding BIS data were within the range of 40–60, whereas for the recommended BIS range between 40 and 60, 69% of corresponding PSIs were within the range of 25–50.

Discussion

Both the PSI and BIS monitors performed equally well ($P_K=0.87$ (0.05) for PSI and 0.86 (0.05) for BIS, respectively) in predicting the estimated propofol effect-site concentrations. According to the definition of the prediction probability $P_K$, this means that if one changes the depth of propofol anaesthesia in our data set a hundred times, the PSI and BIS would correctly indicate this change in 87 and 86 cases, respectively. These reasonably high values were obtained using the i.v. anaesthetic propofol and exceed those $P_K$ values reported in our previous study ($P_K=0.80$ (0.11) for PSI and 0.79 (0.09) for BIS), in which we used the volatile anaesthetic sevoflurane instead.6

Both monitors differ in their algorithm. The PSI revealed generally lower index values than the BIS (Fig. 4), especially at high or even maximal concentrations, as expressed by the parameter $E_{\text{max}}$. We had already observed this effect in our previous study6 using sevoflurane [$E_{\text{max}}=1.3$ (4.3) for PSI and 7.9 (12.1) for BIS] and confirmed this finding using propofol this time [$E_{\text{max}}=0.3$ (1.1) for PSI and 5.3 (6.7) for BIS]. Consistently, the manufacturer of the PSI recommends a range of 25–50 for general anaesthesia,12 which is lower than the recommended range for BIS15 (40–60, Fig. 4).

We reported a higher efflux site constant $K_{EO}$ (that is a lower efflux site half-time $t_{1/2EO}=\ln 2/K_{EO}$) for BIS [$K_{EO}=0.24$ (0.15) min$^{-1}$] when compared with PSI [$K_{EO}=0.13$ (0.08) min$^{-1}$] during sevoflurane anaesthesia and attributed this to differences in time lag, calculation time, and averaging time between the monitors. However, this significant difference in $K_{EO}$ (almost) disappeared when using propofol [$K_{EO}=0.10$ (0.02) min$^{-1}$ for BIS and $K_{EO}=0.09$ (0.03) min$^{-1}$ for PSI]. We assume that the mentioned differences between monitors in time lag, calculation, and averaging time are clinically important only when using an agent with a fast pharmacokinetic such as sevoflurane ($t_{1/2EO} \approx 4$ min) but become irrelevant when using an anaesthetic with a slower kinetic such as propofol ($t_{1/2EO} \approx 7$ min).

The slope $\gamma$ of the sigmoid relationship between propofol effect-site concentration and EEG effect was significantly steeper for PSI ($\gamma=2.2$ (0.6)) when compared with BIS ($\gamma=1.8$ (0.4)), which is a mathematical consequence of the small difference in $E_0$ but large (and significant) difference in $E_{\text{max}}$ (Fig. 4). This difference appeared in the previous sevoflurane study as well [$\gamma=2.1$ (1.4) for PSI and $\gamma=1.8$ (0.8) for BIS], but was statistically not significant.6

We applied the PK model proposed by Schnider and colleagues,6 since it adjusts doses and infusion rates to both age and weight, whereas the alternative PK model published by Marsh and colleagues15 considers weight only. However, it should be noted that ‘there is little conclusive evidence to demonstrate the superiority of any particular model’.16 Application of the Marsh instead of the Schnider model would have yielded similar $P^2$ and $P_K$ values, since it would have affected both the BIS and the PSI monitors in an equal manner. In addition, major and clinical significant differences between the Marsh and the Schnider models are expected to occur, especially in elderly and obese patients,16 however, neither condition existed in our study population.

All patients received midazolam as premedication. Since benzodiazepines alter the EEG,17 this might have influenced the propofol concentration–effect curve. However, the concentration of midazolam necessary to cause EEG changes (>100 ng ml$^{-1}$)17 exceed the peak plasma concentration (35 ng ml$^{-1}$, as extrapolated from Greenblatt and colleagues18 after oral administration of 7.5 mg by a factor of three.

Since this is the first study, to our knowledge, that analyzes the pharmacodynamic effect of propofol on PSI by application of a sigmoid pk/pd model, there are no other PSI pk/pd studies to refer to. However, with regard to the BIS during propofol anaesthesia, the following observations are noteworthy when comparing the pk/pd parameters of our study with the results of other investigators (Table 2): $E_{\text{max}}$ was lower in our study, indicating that we achieved deeper levels of propofol anaesthesia. In addition, we observed a lower $C_{50}$ (1.9 μg ml$^{-1}$) which appears low from a clinical standpoint but is explained by the fact that the study was performed in the absence of any kind of stimulus. Thus, relatively low concentrations of propofol were required to achieve a level of general anaesthesia. Finally, the effect-site efflux constant $K_{EO}$ was lower. The pk/pd parameters described in the literature (Table 2) vary to a considerable amount reflecting the given inter-individual variability, which is an inherent feature of complex biological systems such as the human being.

To take this variability in pk/pd parameters into account, we performed a Bayesian statistics approach in addition to the classic Fisherian statistics: we applied the NONMEM software which estimated a pk/pd model based on fixed effects (the so-called ‘typical values’ in NONMEM parlance) and random effects, which are differentiated into effects due to inter- and intra-individual variabilities.11 As demonstrated in Table 1, the typical values of the pk/pd parameters which characterize a representative patient within a given population differ only slightly from the mean values obtained using the two-stage approach. However, the inter-individual variability of $C_{50}$ and $K_{EO}$ is considerably high, whereas the intra-individual variability $\sigma$ of the PSI (±7.7 index points) and BIS (±6.4 index points) is low. Thus, our results confirm the general rule, that pharmacodynamic variability is pronounced (usually exceeding pharmacokinetic variability), and that inter-individual differences are large, whereas intra-individual differences are much smaller.19

We observed a close sigmoid relationship ($r^2=0.91$ for PSI and 0.92 for BIS) between propofol effect-site concentration...
and EEG effect (i.e. BIS and PSI). In the absence of a gold-standard defining depth of anaesthesia, effect-site concentration is a widely accepted surrogate parameter. 20–23 Consequently, both the BIS and the PSI monitors can be regarded as monitors of depth of anaesthesia.

We noticed a close and significant linear correlation between PSI and BIS ($r^2 = 0.87$) during propofol anaesthesia which exceeded our previous findings 4 obtained using sevoflurane ($r^2 = 0.75$). Nevertheless, we only found a poor agreement between the recommended ranges for PSI (25–50) and BIS (40–60), so that index values—which were within the recommended range in one monitor—were outside the range in the other monitor, as was previously reported by Schneider and colleagues.24 Other authors 24–26 reported a rather modest correlation between PSI and BIS with a coefficient of determination $r^2$ ranging between 0.4424 and 0.72.26 However, their data were based on a previous version of either the electrodes or the monitors, or used a different hypnotic regimen.

PSI and BIS have already been compared in the past and disagreeing assessments were published: PSI and BIS performed equally well in predicting unconsciousness26 [receiver operating characteristics, ROC $= 0.98 (0.05)$ for PSI and $0.97 (0.05)$ for BIS] and detecting awareness 27 [PK $= 0.69 (0.03)$ for PSI and $0.68 (0.03)$ for BIS]; however, the latter ability was deemed to be nonetheless insufficient. 27 In contrast, PSI was found to be superior to BIS in detecting consciousness [ROC $= 0.95 (0.04)$ for PSI and ROC $= 0.79 (0.04)$ for BIS] according to Chen and colleagues, 28 and Adesanya and colleagues25 reported that BIS was consistently better in predicting oversedation than the PSI (area under the curve $= 0.92$ for BIS and $0.78$ for PSI).

The PSI was approved in 2002 and has been evaluated since then in 15 publications (retrieval at PubMed on October 15, 2009). In contrast, the BIS has already been evaluated since 1996, subjected to 1417 publications (retrieval at PubMed on October 15, 2009) and applied to more than 34 million patients (according to manufacturer’s information). Hence, BIS technology is thought to be the most validated form of depth of anaesthesia monitoring. PSI, on the other hand, was only introduced in 2002 and has been used in more than 150 publications.

We conclude that both the PSI and the BIS monitors predict depth of propofol anaesthesia with a similar and sufficient high probability. The major difference between the two monitors (besides their algorithm) refers to the fact that PSI values were lower than the BIS values by $\approx 10–15$ index points resulting in a lower recommended range (25 to 50 for PSI, and 40 to 60 for BIS) for general anaesthesia.

Acknowledgements

The support of Prof. Dr. Friedrich Bootz, MD, professor and chairman of otorhinolaryngologic surgery, and Priv.-Doz. Dr. Sabine Keiner, MD, vice chairman of otorhinolaryngologic surgery is gratefully acknowledged. Data presented here are part of the doctoral thesis of M.K.

Conflict of interest

None declared.

Table 2 Pharmacokinetic and -dynamic parameters of BIS during propofol anaesthesia as obtained by different authors. $E_0$, EEG effect without anaesthesia; $E_{\text{max}}$, EEG effect corresponding to maximum drug effect; $C_{50}$, propofol effect-site concentration that caused 50% of the maximum EEG effect; $\gamma$, slope of the sigmoid relationship; $k_{e0}$, effect-site efflux constant; $r^2$, coefficient of determination. Data are given as mean (so), mean (95% confidence interval), or typical value

<table>
<thead>
<tr>
<th>Author</th>
<th>PK model</th>
<th>$E_0$</th>
<th>$E_{\text{max}}$</th>
<th>$C_{50}$ (µg ml$^{-1}$)</th>
<th>$\gamma$</th>
<th>$k_{e0}$ (min$^{-1}$)</th>
<th>$r^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Billard and colleagues$^{10}$</td>
<td>Marsh and colleagues$^{15}$</td>
<td>91.3 (7.1)</td>
<td>14.8 (8.6)</td>
<td>3.4</td>
<td>5.3 (2.1)</td>
<td>0.20</td>
<td>0.83</td>
</tr>
<tr>
<td>Ellerkmann and colleagues$^{21}$</td>
<td>Marsh and colleagues$^{15}$</td>
<td>95.8 (3.2)</td>
<td>25.0 (4.8)</td>
<td>2.28 (0.81)</td>
<td>3.54 (1.80)</td>
<td>0.38 (0.15)</td>
<td>0.92 (0.06)</td>
</tr>
<tr>
<td>Mourisse and colleagues$^{29}$ (blink reflex)</td>
<td>Marsh and colleagues$^{15}$</td>
<td>96.4 (95.6–97.3)</td>
<td>24.0 (23.0–25.0)</td>
<td>3.10 (2.82–3.38)</td>
<td>4.67 (3.98–5.47)</td>
<td>0.34 (0.29–0.40)</td>
<td>0.88 (0.86–0.91)</td>
</tr>
<tr>
<td>Mourisse and colleagues$^{30}$ (tetanus)</td>
<td>Marsh and colleagues$^{15}$</td>
<td>92.0 (7.0)</td>
<td>5.3 (6.7)</td>
<td>1.4 (0.52)</td>
<td>1.75 (0.41)</td>
<td>0.10 (0.02)</td>
<td>0.92 (0.03)</td>
</tr>
<tr>
<td>Current study</td>
<td>Schnider and colleagues$^{6}$</td>
<td>96</td>
<td>20</td>
<td>2.4</td>
<td>3.1</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Doufas and colleagues$^{31}$</td>
<td>Schnider and colleagues$^{6}$</td>
<td>100</td>
<td>25</td>
<td>2.8</td>
<td>1.4</td>
<td>0.20</td>
<td></td>
</tr>
<tr>
<td>Struys and colleagues$^{32}$</td>
<td>Schnider and colleagues$^{6}$</td>
<td>95.9</td>
<td>8.4</td>
<td>4.92</td>
<td>2.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vanluchene and colleagues$^{33}$</td>
<td>Schnider and colleagues$^{6}$</td>
<td>95.9</td>
<td>8.4</td>
<td>4.92</td>
<td>2.69</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Funding
This study was supported by the Department of Anaesthesiology and Intensive Care Medicine, University of Bonn, Bonn, Germany. Both Aspect Medical Systems, Newton, MA, USA, and Hospira Incorporated, Lake Forrest, IL, USA, supplied complementary EEG electrodes for study purposes. Hospira Incorporated provided the PSA-4000 monitor.

References
31. Doufas AG, Bakhshandeh M, Bjorksten AR, Shafer SL, Sessler DI. Induction speed is not a determinant of propofol pharmacodynamics. Anesthesiology 2004; 101: 1112–21